Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years

被引：3
|
作者：
Suzuki, Hidenobu [1 ]
Hibino, Hiroyuki [2 ]
Inoue, Yuichi [3 ]
Takaya, Atsuhiko [2 ]
机构：
[1] Suzuki Clin, Dept Psychiat, Tokyo, Japan
[2] Fukui Kinen Hosp, Dept Psychiat, Yokohama, Kanagawa, Japan
[3] Shakomae Kokorono Clin, Dept Psychiat, Tokyo, Japan
来源：
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 2016年 / 36卷 / 04期
关键词：
D O I：
10.1097/JCP.0000000000000533
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：405 / 406
页数：3
相关论文
共 50 条
  • [1] Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia
    Chen, Wen-Yin
    Lin, Shih-Ku
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (05) : 492 - 495
  • [2] Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability
    Singh, Sourabh Moti
    Haddad, Peter M.
    Husain, Nusrat
    Heaney, Eamonn
    Tomenson, Barbara
    Chaudhry, Imran B.
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2016, 6 (03) : 162 - 171
  • [3] Long term benefits of treatment with risperidone long-acting injection in patients with schizophrenia
    Turner, MS
    Urquhart, E
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S399 - S399
  • [4] COST OF LONG-ACTING RISPERIDONE INJECTION VERSUS LONG-ACTING PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA
    Omelyanovsky, V
    Avxentyeva, M.
    Ivakhnenko, O.
    Khailov, P.
    Tsfasman, F. M.
    Krysanov, I
    Zorin, N.
    VALUE IN HEALTH, 2012, 15 (07) : A338 - A338
  • [5] Optimizing treatment with risperidone long-acting injections
    Ceskova, E.
    ACTA PSYCHIATRICA SCANDINAVICA, 2012, 126 (06) : 479 - 480
  • [6] Long-acting risperidone injection
    Love, RC
    Conley, RJ
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (17) : 1792 - 1800
  • [7] Comparison of subjective experiences and effectiveness of first-generation long-acting injectable antipsychotics and risperidone long-acting injectables in patients with schizophrenia (vol 36, pg 492, 2016)
    Chen, W-Y
    Lin, S-K.
    Lin, S. K.
    Pan, C. H.
    Chen, C. H.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2018, 38 (05) : 434 - 434
  • [8] Treatment retention of risperidone long-acting injection in patients with early-onset schizophrenia in Japan
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    Inoue, Yuichi
    Takaya, Atsuhiko
    ASIAN JOURNAL OF PSYCHIATRY, 2017, 27 : 137 - 138
  • [9] Long-acting injectable risperidone for the treatment of schizophrenia
    Moeller, Hans-Juergen
    DRUGS, 2007, 67 (11) : 1541 - 1566
  • [10] COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
    Carroll, S. M.
    Jemiai, N.
    Suter, B.
    O'Donohoe, P.
    Skjoldborg, U.
    Moller, J.
    Kleivenes, O. K.
    Novick, D.
    VALUE IN HEALTH, 2009, 12 (07) : A358 - A358
12345